Personalised RNA Interference to Enhance the Delivery of Individualised Cytotoxic and Targeted therapeutics
PREDICT will define the next generation of predictive biomarkers through the integration of clinical trial design with functional cancer genomics to enable personalised medicine and the cost-effective delivery of beneficial cancer therapeutics.
The PREDICT Consortium was established in 2009 to coordinate single drug clinical trials with personalised tumour functional genomic analysis to define patient-specific drug sensitivity pathways and biomarkers predictive of drug response.
The consortium integrates expertise in renal carcinoma clinical trial recruitment, whole genome sequencing technologies, ex vivo cancer cell line cultures and personalised rna interference screening technologies.
The PREDICT Consortium recently created Ocelot, a web-based tool for cancer researchers which enables efficient hypothesis-driven exploration of genomic data produced in clinical trials. Read more »